According to a FDA press release this week, testosterone drug makers must change the products’ labels to warn they are approved for only certain disorders, not to help men treat aging symptoms.
Popular blockbuster drugs, like AbbVie Inc.’s AndroGel and Eli Lilly & Co.’s Axiron, are being restricted and warnings are being required in the labels about a potential risk of heart attack and stroke from using testosterone.
According to Bloomberg, AndroGel ranked second in AbbVie’s drug sales last year, with $934 million.